Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

Figure 3

Effects of GNF-2 and Dasatinib on PDLTCs of Ph + ALL patients expressing BCR/AB-T315I. Proliferation/citotoxicity was determined by the metabolic activity of cells given by the reduction rate of XTT to formazan. The means +/- SD of triplicates from one representative experiment out of three performed are shown. (A) XTT assay using Ph- PDLTCs (HP) upon exposure to 1.25, 2.5 and 5 μM GNF-2 and 125, 25 and 500 nM Dasatinib. (B) XTT assay using Ph + PDLTCs (KÖ) expressing BCR/ABL-T315I upon exposure to 1.25, 2.5 and 5 μM GNF-2 and 125, 250 and 500 nM Dasatinib.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us